Skip to main content
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
editorial
. 2024 Jan 15;25(2):1061. doi: 10.3390/ijms25021061

Special Issue “Neurogenetics in Neurology”

Antonio Orlacchio 1,2
PMCID: PMC10815939  PMID: 38256134

With the rapid developments in molecular genetics and genomics, this Special Issue collates works outlining ultra-modern scientific research.

The Special Issue entitled of the International Journal of Molecular Sciences includes six papers, among which is a research article, four reviews and a perspective piece, that highlight the remarkable advances made in the cognition of basic biological processes and their consequences for human health. Embracing disparate reasons, the six papers exhibited here cast a light on various aspects of molecular genetics and genomics, highlighting the tangled mutual influence of genetic information, cellular processes and physopathogenic mechanisms.

A key theme emerging from these works is the growing knowledge of the molecular mechanisms underlying various genetics-based diseases affecting the nervous system. Understanding of the pathogenesis of these diseases is increased by articulating strategies to use this knowledge to provide novel therapeutic tools. In their paper, Kuznitsov-Yanovsky et al. expose the slowed maturation of X-originating fragile neurons at the transcriptomic and functional levels because of delayed neuronal growth and maturation, identifying the related damaged neurodevelopmental pathways, i.e., mainly the TGF_/BMP signaling pathway. These results provide new insights into the molecular pathway by which fragile X mental retardation protein (FMRP) deficiency acts on the neuronal network development [1].

Moreover, the study by Monfrini et al., highlights that brain calcification can denote the epiphenomenon of many systemic and genetic conditions. An associated clinical appearance (such as dysmorphism, cutaneous abnormalities or immunological traits) can assist in the procedure of a differential diagnosis. Interestingly, several genes accountable for these forms are implicated in the mechanisms of angiogenesis and in the blood–brain barrier (BBB), suggesting common ways that could be blocked by therapeutic approaches to these conditions [2].

Improvements in technology, such as deep convolutional neural networks, have also enabled the comprehensive exploration of the molecular mechanisms underlying diverse diseases affecting the nervous system. The review by Dr. Cencioni et al., summarizes the existing information on glioblastoma multiforme (GBM) metabolism, with a detailed focus on the control of the Myc oncogene that, in turn, rules the activation of metabolic signals, establishing the formation of a GBM tumor [3,4,5].

Furthermore, Faravelli et al. exhibited the multifaced function of the survival motor neuron (SMN) protein and the influence of the loss of distinct roles of SMN in the pathogenesis of SMA. The weakening of snRNP assembly and the SMN complex has been strongly associated with the residual levels of SMN activity in cellular models of SMA and regulates downstream tissue-specific splicing alterations. The translational effects of these observations indicate that restoring the role of snRNP in animal models of SMA is sufficient to save the phenotype [6,7].

The biological and clinical importance of microRNAs (miRNAs or miRs) is clearly highlighted in the work of Kumar and Li., where they review the present advancement in miR-30c in the pathogenesis of various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and stroke, and its therapeutic capability. Bioinformatic analysis and experimental indication recommend that miR-30c controls many genes as targets that are linked with several pathogenic processes, such as autophagy, apoptosis, ER stress, inflammation, oxidative stress, thrombosis, and neurovascular function, thus contributing to the pathophysiology of diverse neurological diseases. In this context, the therapeutic targeting of miR-30c via synthetic mimics or inhibitors is under evaluation [8,9,10].

The last manuscript in this Special Issue by Mercurio et al. reviews recent papers producing long-range interaction maps (via HiC, RNApolII ChIA-PET, Capture-HiC or PLACseq) and overlapping the recognized long-range networking DNA segments with DNA sequence modifications associated with neurodevelopmental disorders (NDD) (such as schizophrenia, bipolar disorder, and autism) and traits (intelligence). Hence, long-range interaction maps, in combination with DNA changes noticed in association with NDD, can be used as “pointers” to detect novel candidate disease-applicable genes. The functional handling of the long-range communication network, including enhancers and promoters via CRISPR-Cas9-based approaches, is beginning to be probed for the functional meaning of recognized interactions and the enhancers and the genes involved, enlightening our understanding of neural growth and its pathology [11].

As indicated by these diverse contributions to the Special Issue, a common storyline appears: the complex connection between genetics, molecular mechanisms, and disease. These works cooperatively highlight the outstanding strides we have taken in solving the molecular complexities of diverse diseases, while also highlighting the prospects that stay ahead.

Overall, the papers in this Special Issue highlight the latest progress in molecular genetics and genomics and improve our existing knowledge of the key mechanisms in this field. These conclusions not only showcase the achievements of the past, but also pave the way for awakening possibilities of further investigation in the field of molecular genetics and genomics.

In closure, I would like to present my greatest thanks to the authors, reviewers, and the Editorial team for their precious contributions to this Special Issue. I hope that these manuscripts will not only improve our perception of molecular genetics and genomics, but also inspire further analysis and novelty in this dynamic and ever-evolving field.

Conflicts of Interest

The author declares no conflict of interest.

List of Contributions

  1. Kuznitsov-Yanovsky, L.; Shapira, G.; Gildin, L.; Shomron, N; Ben-Yosef, D. Transcriptomic Analysis of Human Fragile X Syndrome Neurons Reveals Neurite Outgrowth Modulation by the TGFβ/BMP Pathway. Int. J. Mol. Sci. 2022, 23, 9278. https://doi.org/10.3390/ijms23169278.

  2. Monfrini, E.; Arienti, F.; Rinchetti, P.; Lotti, F.; Riboldi, G.M. Brain Calcifications: Genetic, Molecular, and Clinical Aspects. Int. J. Mol. Sci. 2023, 24, 8995. https://doi.org/10.3390/ijms24108995.

  3. Cencioni, C.; Scagnoli, F.; Spallotta, F.; Nasi, S.; Illi, B. The “Superoncogene” Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. Int. J. Mol. Sci. 2023, 24, 4217. https://doi.org/10.3390/ijms24044217.

  4. Faravelli, I.; Riboldi, G.M.; Rinchetti, P.; Lotti, F. The SMN Complex at the Crossroad between RNA Metabolism and Neurodegeneration. Int. J. Mol. Sci. 2023, 24, 2247. https://doi.org/10.3390/ijms24032247.

  5. Kumar, M; Li, G. Emerging Role of MicroRNA-30c in Neurological Disorders. Int. J. Mol. Sci. 2022, 24, 37. https://doi.org/10.3390/ijms24010037.

  6. Mercurio, S.; Pozzolini, G.; Baldi, R.; Barilà, S.E.; Pitasi, M.; Catona, O.; D’Aurizio, R.; Nicolis, S.K. Hooked Up from a Distance: Charting Genome-Wide Long-Range Interaction Maps in Neural Cells Chromatin to Identify Novel Candidate Genes for Neurodevelopmental Disorders. Int. J. Mol. Sci. 2023, 24, 1164. https://doi.org/10.3390/ijms24021164.

Funding Statement

This work was supported by the Italian Ministry of Health [Grant no. RF19.12] and the Department of Medicine and Surgery of the University of Perugia [Fondo Ricerca di Base, Grants no. DSCH_BASE19_ORLACCHIO and RICERCABASE_2020_ORLACCHIO].

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Yu J., Woo Y., Kim H., An S., Park S.K., Jang S.K. FMRP Enhances the Translation of 4EBP2 mRNA during Neuronal Differentiation. Int. J. Mol. Sci. 2023;24:16319. doi: 10.3390/ijms242216319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Xu X., Sun H., Luo J., Cheng X., Lv W., Luo W., Chen W.J., Xiong Z.Q., Liu J.Y. The Pathology of Primary Familial Brain Calcification: Implications for Treatment. Neurosci. Bull. 2023;39:659–674. doi: 10.1007/s12264-022-00980-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu Z., Wang S., Yu K., Chen K., Zhao L., Zhang J., Dai K., Zhao P. The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma. J. Transl. Med. 2023;21:863. doi: 10.1186/s12967-023-04740-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kimura K., Jackson T.L.B., Huang R.C.C. Interaction and Collaboration of SP1, HIF-1, and MYC in Regulating the Expression of Cancer-Related Genes to Further Enhance Anticancer Drug Development. Curr. Issues Mol. Biol. 2023;45:9262–9283. doi: 10.3390/cimb45110580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Illi B., Nasi S. Myc beyond Cancer: Regulation of Mammalian Tissue Regeneration. Pathophysiology. 2023;30:346–365. doi: 10.3390/pathophysiology30030027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Meneri M., Abati E., Gagliardi D., Faravelli I., Parente V., Ratti A., Verde F., Ticozzi N., Comi G.P., Ottoboni L., et al. Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples. Biomedicines. 2023;11:1254. doi: 10.3390/biomedicines11051254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.De Siqueira Carvalho A.A., Tychon C., Servais L. Newborn screening for spinal muscular atrophy—What have we learned? Expert Rev. Neurother. 2023;23:1005–1012. doi: 10.1080/14737175.2023.2252179. [DOI] [PubMed] [Google Scholar]
  • 8.Li T., Tan X., Tian L., Jia C., Cheng C., Chen X., Wei M., Wang Y., Hu Y., Jia Q., et al. The role of Nurr1-miR-30e-5p-NLRP3 axis in inflammation-mediated neurodegeneration: Insights from mouse models and patients’ studies in Parkinson’s disease. J. Neuroinflamm. 2023;20:274. doi: 10.1186/s12974-023-02956-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pagoni M., Cava C., Sideris D.C., Avgeris M., Zoumpourlis V., Michalopoulos I., Drakoulis N. miRNA-Based Technologies in Cancer Therapy. J. Pers. Med. 2023;13:1586. doi: 10.3390/jpm13111586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ivraghi M.S., Zamanian M.Y., Gupta R., Achmad H., Alsaab H.O., Hjazi A., Romero-Parra R.M., Alwaily E.R., Hussien B.M., Hakimizadeh E. Neuroprotective effects of gemfibrozil in neurological disorders: Focus on inflammation and molecular mechanisms. CNS Neurosci. Ther. 2023 doi: 10.1111/cns.14473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zerva I.K., Bonti E. Developmental Language Disorders in Childhood and Adolescence. IGI Global; Hershey, PA, USA: 2023. How “Specific” Are Specific Learning Disabilities after All? pp. 157–168. Chapter 12. [Google Scholar]

Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES